AKTIPAK
LOE ApproachingNDATOPICALGEL
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTIPAK is a topical gel approved in 2000 for an unknown indication, sponsored by Biofrontera. The mechanism of action and pharmacologic class are not specified in available data. This product's exact therapeutic target remains undisclosed.
LOE Approaching
As LOE approaches, commercial team size will likely contract; positions are shifting toward retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AKTIPAK currently shows zero linked job openings, indicating minimal active hiring. Working on this product offers limited career growth given its LOE trajectory and lack of expansion pipeline.
Brand ManagerField Sales Representative
Worked on AKTIPAK at Biofrontera? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.